Retrieve available abstracts of 7 articles: HTML format
Single Articles
June 2025
QI C, Liu C, Peng Z, Zhang Y, et al Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of
physician's choice for previously treated advanced gastric or gastro-oesophageal
junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
Lancet. 2025;405:2049-2060. PubMedAbstract available
May 2025
SUNDAR R, Nakayama I, Markar SR, Shitara K, et al Gastric cancer.
Lancet. 2025 May 1:S0140-6736(25)00052-2. doi: 10.1016/S0140-6736(25)00052. PubMedAbstract available
June 2024
SINGH S, Halperin D, Myrehaug S, Herrmann K, et al [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high?dose long-acting
octreotide for the treatment of newly diagnosed, advanced grade 2-3,
well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an
open-label, randomise
Lancet. 2024;403:2807-2817. PubMedAbstract available
LIOU JM, Malfertheiner P, Smith SI, El-Omar EM, et al 40 years after the discovery of Helicobacter pylori: towards elimination of H
pylori for gastric cancer prevention.
Lancet. 2024;403:2570-2572. PubMed
December 2023
SMYTH EC, Sundar R Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in
HER2-positive gastro-oesophageal cancer.
Lancet. 2023;402:2168-2170. PubMed
May 2023
SHITARA K, Lordick F, Bang YJ, Enzinger P, et al Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative,
untreated, locally advanced unresectable or metastatic gastric or
gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre,
randomised, double-blind, phase 3 tr
Lancet. 2023;401:1655-1668. PubMedAbstract available
March 2023
O'MAHONY D, Power SP, Power DG Human epidermal growth factor receptor 2-positive metastatic gastric cancer in
complete sustained remission with trastuzumab.
Lancet. 2023;401:772. PubMed